Hospital
Houston County Healthcare Authority
Houston County Healthcare Authority was paid $4.92M by Medicaid between Jan 2018 and Nov 2024, across 83 billing codes. Its largest line is 99284, emergency room visit (serious) — 35% of everything it billed.
33Billing provider infoHOUSTON COUNTY HEALTHCARE AUTHORITY
DOTHAN, AL 36301
DOTHAN, AL 36301
33aNPI1164403861assigned 11/09/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.92M
24GClaims171,143
24DCodes billed83
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#14 of 77
Median peer was paid$1.13M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MILLER, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,562 | $585K | |
| 2019 | 29,844 | $572K | |
| 2020 | 17,067 | $369K | |
| 2021 | 21,620 | $522K | |
| 2022 | 24,311 | $690K | |
| 2023 | 27,116 | $989K | |
| 2024incomplete | 21,623 | $1.20M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 26,499 | 24,690 | $1.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 3,058 | 2,883 | $962K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 22,752 | 21,207 | $827K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.9% | 11,169 | 9,140 | $339K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.1% | 25,076 | 21,855 | $199K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 10,072 | 8,750 | $95K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 2,914 | 2,738 | $62K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 1,396 | 1,328 | $59K |
| G0378 | Hospital observation service, per hour | <1% | 1,549 | 1,211 | $45K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,373 | 755 | $41K |
| 80053 | Comprehensive metabolic panel | <1% | 4,000 | 2,828 | $40K |
| 81001 | <1% | 9,986 | 9,247 | $37K |
71 more codes
| 80076 | <1% | 5,877 | $36K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,906 | $35K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 873 | $33K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 248 | $31K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 738 | $29K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 472 | $28K |
| 80047 | <1% | 4,253 | $25K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,162 | $24K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 494 | $24K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 598 | $22K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,281 | $19K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 807 | $18K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 765 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,333 | $12K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 45 | $11K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 130 | $10K |
| 84484 | <1% | 1,300 | $10K | |
| 87081 | <1% | 1,092 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,967 | $9K |
| 46505 | <1% | 42 | $9K | |
| 83735 | <1% | 1,146 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 200 | $8K |
| 87486 | <1% | 200 | $8K | |
| 87581 | <1% | 200 | $8K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 86 | $8K |
| 59025 | Fetal non-stress test | <1% | 1,243 | $7K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 224 | $5K |
| 81002 | <1% | 1,771 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 793 | $4K |
| 85014 | <1% | 4,506 | $4K | |
| 83690 | <1% | 671 | $4K | |
| 81025 | <1% | 1,099 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 45 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 330 | $3K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,630 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 192 | $2K |
| 87420 | <1% | 138 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,895 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,175 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 778 | $1K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 109 | $716.76 |
| 94664 | <1% | 108 | $602.86 | |
| 77336 | <1% | 36 | $445.06 | |
| 95812 | <1% | 14 | $424.06 | |
| 83605 | <1% | 42 | $403.56 | |
| 84702 | <1% | 26 | $395.37 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 43 | $214.37 |
| 87430 | <1% | 17 | $208.52 | |
| 87807 | <1% | 14 | $172.90 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 368 | $153.00 |
| 85610 | <1% | 28 | $141.52 | |
| 73110 | <1% | 12 | $136.44 | |
| 73610 | <1% | 13 | $136.44 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 542 | $116.07 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 101 | $65.00 |
| 87210 | <1% | 12 | $54.45 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13 | $27.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 70 | $26.64 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $18.46 |
| 85027 | <1% | 13 | $10.76 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 405 | $5.41 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 557 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 173 | $0.00 |
| 94799 | 0% | 12 | $0.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 104 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 233 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 51 | $0.00 |
| 94760 | 0% | 95 | $0.00 | |
| 80320 | 0% | 84 | $0.00 | |
| 36591 | 0% | 274 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, ROBERT (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.